Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

TTarsus Pharmaceuticals, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
T

Tarsus Pharmaceuticals, Inc.

$77.08Close · Sep 22, 2026
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $173.91M. Net result −$18.55M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $173.91M. Running result $173.91M. License And Collaboration: $0. Product: $173.91M.
  • Cost of revenue: −$12.11M. Running result $161.8M.
  • Gross profit: $161.8M. Running result $161.8M.
  • Research and development: −$31.01M. Running result $130.79M.
  • Selling, general and administrative: −$150.7M. Running result −$19.91M.
  • Operating income: −$19.91M. Running result −$19.91M.
  • Other income: $4.07M. Running result −$15.84M.
  • Pre-tax loss: −$15.84M. Running result −$15.84M.
  • Income tax expense: −$2.72M. Running result −$18.55M.
  • Net loss: −$18.55M. Running result −$18.55M.